Form:RCT Study: Difference between revisions

Revision as of 07:16, 23 September 2024

This is the "RCT Study" form. To create a page with this form, enter the page name below; if a page with that name already exists, you will be sent to a form to edit that page.

@@ Line 175: / Line 175: @@
 '''Outcome type:''' {{#info: As specificed by the authors| note}} {{{field|Outcome type|input type=radiobutton|mandatory|default=?|values=?,Primary,Secondary,Others,NI}}}
-'''Outcome name:''' {{{field|Outcome name|input type=text with autocomplete|mandatory|default=?|delimiter=,|values=Additional medication,Anorexia/Cachexia,Antibodies,Anxiety,Appetite,Arterial inflow,BMD (Bone Mineral Density),Body composition,Carnitine level,Carotenoid concentration,Cerebral oedema,CINV (Chemotherapy-Induced Nausea and Vomiting),Cognitive functioning,Cognitive impairment,Depression,Dermatitis,DFS (Disease-Free Survival),Diarrhoe,Distress,Dysgeusia,EFS (Event-Free Survival),Ejection fraction,Emesis,Erectile dysfunction,Erythema,Esophagitis,Fatigue,Fever,Fibrosis,Folic acid level,Frequency of rescue analgesics,Functionality,Haematological indices,Haematological toxicity,Hand-foot syndrome,Hand grip strength,Hepatotoxicity,Hot flushes,Hormone level,Ileus (intestinal obstruction),Incidence of acute GVHD (Graft-Versus-Host Disease),Infection,Interaction with cancer treatment,Laboratory parameters,Length of hospital stay,LFS (Local-Free Survival),Lymphedema,Menopausal symptoms,Mental status/ function,MFS (Metastases-Free Survival),Mood/Affect,Mortality rate,MTD (Maximum Tolerated Dose),Mucositis,Musculoskeletal symptoms,Nausea,Nausea and Vomiting,Nerve conductive velocity,Neurotoxicity,Neutropenia,Non-haematological indices,Nutrition status,Objective signs and subjective symptoms,Oral ulcus,OS (Overall Survival),Ototoxicity,Pain,PD (Pharmacodynamics),Performance Status,Peripheral neuropathy,PFS (Progression-Free Survival),Pharyngitis,Physical functioning,PK (Pharmacokinetics),Postoperative opiate consumption,PSADT (Prostate-Specific Antigen Doubling Time),PSA level (Prostate-Specific Antigen),Quality of life,Recurrence rate,Reduction of complication rates,REE (Resting Energy Expenditure),Relaxation,Restoration of bowel function after surgery,RFS (Recurrence-Free Survival),Salivary gland function,Selenium level,Seroconversion,Shoulder mobility,Side effects of androgen deprivation/suppression,Side effects of tooth extraction,Skeletal morbidity-free survival,Sleep,Stress,Taste alteration,Tea polyphenol uptake,Thromboembolic event rates,Toxicity,Treatment interruption,Tumor progression,Tumor response,Vaginal atrophy,Vitamin A level,Vitamin B6 level,Vitamin B12 level,Vitamin B17 level,Vitamin C level,Vitamin D level,Vitamin E level,Vomiting,Weight,Well-being,Wound healing,Wound odour,Xerostomia,Zinc level,Unspecified effects,NI,?}}}
+'''Outcome name:''' {{{field|Outcome name|input type=text with autocomplete|mandatory|default=?|delimiter=,|values=Additional medication,Anorexia/Cachexia,Antibodies,Anxiety,Appetite,Arterial inflow,BMD (Bone Mineral Density),Body composition,Carnitine level,Carotenoid concentration,Cerebral oedema,CINV (Chemotherapy-Induced Nausea and Vomiting),Cognitive functioning,Cognitive impairment,Depression,Dermatitis,DFS (Disease-Free Survival),Diarrhoe,Distress,Dysgeusia,EFS (Event-Free Survival),Ejection fraction,Emesis,Erectile dysfunction,Erythema,Esophagitis,Fatigue,Fever,Fibrosis,Folic acid level,Frequency of rescue analgesics,Functionality,Haematological indices,Haematological toxicity,Hand-foot syndrome,Hand grip strength,Hepatotoxicity,Hot flushes,Hormone level,Ileus (intestinal obstruction),Incidence of acute GVHD (Graft-Versus-Host Disease),Infection,Interaction with cancer treatment,Laboratory parameters,Length of hospital stay,LFS (Local-Free Survival),Lymphedema,Menopausal symptoms,Mental status/ function,MFS (Metastases-Free Survival),Mood/Affect,Mortality rate,MTD (Maximum Tolerated Dose),Mucositis,Musculoskeletal symptoms,Nausea,Nausea and Vomiting,Nerve conduction velocity,Neurotoxicity,Neutropenia,Non-haematological indices,Nutrition status,Objective signs and subjective symptoms,Oral ulcus,OS (Overall Survival),Ototoxicity,Pain,PD (Pharmacodynamics),Performance Status,Peripheral neuropathy,PFS (Progression-Free Survival),Pharyngitis,Physical functioning,PK (Pharmacokinetics),Postoperative opiate consumption,PSADT (Prostate-Specific Antigen Doubling Time),PSA level (Prostate-Specific Antigen),Quality of life,Recurrence rate,Reduction of complication rates,REE (Resting Energy Expenditure),Relaxation,Restoration of bowel function after surgery,RFS (Recurrence-Free Survival),Salivary gland function,Selenium level,Seroconversion,Shoulder mobility,Side effects of androgen deprivation/suppression,Side effects of tooth extraction,Skeletal morbidity-free survival,Sleep,Stress,Taste alteration,Tea polyphenol uptake,Thromboembolic event rates,Toxicity,Treatment interruption,Tumor progression,Tumor response,Vaginal atrophy,Vitamin A level,Vitamin B6 level,Vitamin B12 level,Vitamin B17 level,Vitamin C level,Vitamin D level,Vitamin E level,Vomiting,Weight,Well-being,Wound healing,Wound odour,Xerostomia,Zinc level,Unspecified effects,NI,?}}}
 '''Outcome specification:''' {{{field|Outcome specification|input type=textarea|default=?}}}